3-Jan-2025
No headlines found.
Business Wire (Tue, 12-Nov 4:30 PM ET)
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
Business Wire (Thu, 31-Oct 7:30 AM ET)
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
Business Wire (Thu, 24-Oct 7:08 AM ET)
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
Syros Pharmaceuticals trades on the NASDAQ stock market under the symbol SYRS.
As of January 3, 2025, SYRS stock price climbed to $0.24 with 6,249,821 million shares trading.
SYRS has a beta of 3.65, meaning it tends to be more sensitive to market movements. SYRS has a correlation of 0.03 to the broad based SPY ETF.
SYRS has a market cap of $6.51 million. This is considered a Sub-Micro Cap stock.
Last quarter Syros Pharmaceuticals reported $0 in Revenue and -$.16 earnings per share. This fell short of revenue expectation by $-450,000 and exceeded earnings estimates by $.56.
In the last 3 years, SYRS traded as high as $38.50 and as low as $.18.
The top ETF exchange traded funds that SYRS belongs to (by Net Assets): VTI, VXF, IWC.
SYRS has underperformed the market in the last year with a return of -96.6%, while the SPY ETF gained +27.8%. In the last 3 month period, SYRS fell short of the market, returning -87.5%, while SPY returned +4.6%. However, in the most recent 2 weeks SYRS has outperformed the stock market by returning +21.5%, while SPY returned +0.1%.
SYRS support price is $.21 and resistance is $.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SYRS shares will trade within this expected range on the day.